Ani pharmaceuticals inc (ANIP)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11
Cash Flows From Operating Activities
Net (loss)/Income

-1,366

6,094

16,359

17,501

13,693

15,494

435

118

22

-1,076

7,473

5,296

3,740

3,934

7,890

9,906

12,352

15,375

33,504

35,691

29,757

28,747

11,175

5,620

3,400

301

0

0

0

-

-

-

-44,622

-51,608

0

0

0

Adjustments to reconcile net loss to net cash and cash equivalents provided by operating activities:
Stock-based compensation

9,931

9,217

8,601

7,926

7,115

6,782

6,376

6,056

6,081

6,090

6,048

5,938

6,348

6,067

5,826

5,581

4,393

3,856

3,421

2,994

3,944

3,423

2,752

2,062

83

36

0

0

0

-

-

-

1,190

1,177

0

0

0

Deferred taxes

-28,212

-9,134

-9,032

-6,898

-4,849

-5,180

5,581

4,279

3,799

3,560

-12,429

-10,182

-9,565

-8,911

-3,016

-2,725

-2,252

-1,877

-14,404

-14,046

-14,165

-14,459

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation and amortization

39,692

44,612

43,734

42,809

41,650

33,742

32,078

30,629

29,417

27,928

26,718

25,585

24,440

22,343

18,642

14,723

10,182

6,900

6,071

5,211

4,502

3,878

3,033

2,228

1,668

1,110

814

576

681

567

455

347

137

148

0

0

0

Acquired in-process research and development ("IPR&D")

6,077

2,324

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock warrant expense - noncash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

204

0

0

0

Loss on disposal of property and equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-365

-367

0

0

0

Non-cash interest relating to convertible notes and loan cost amortization

5,333

7,024

7,752

7,994

8,231

8,465

8,335

8,113

7,891

7,666

7,583

7,589

7,438

7,281

7,117

6,925

6,873

6,831

5,694

3,947

2,242

559

434

434

239

217

0

0

0

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Accounts receivable, net

14,969

7,287

3,053

18,848

11,298

4,743

4,162

602

8,104

12,893

14,697

19,951

24,216

23,963

25,832

16,682

5,110

4,635

7,075

11,086

6,464

4,784

5,055

1,367

5,003

7,081

0

0

0

-

-

-

-

-

-

-

-

Inventories, net

2,438

7,660

6,168

5,343

5,341

379

-869

-4,751

-11,599

-5,356

-6,683

355

4,213

1,938

3,662

1,493

3,185

5,869

6,395

6,257

5,115

3,468

4,005

3,327

2,052

708

0

0

0

-

-

-

-

-

-

-

-

Prepaid expenses and other current assets

-1,073

-403

-117

1,044

1,314

1,142

421

-253

-538

17

1,389

-2,181

873

647

935

2,674

550

314

541

277

135

558

19

242

252

188

359

-23

94

88

-225

-241

-434

-1,682

0

0

0

Accounts payable

1,702

5,039

3,346

227

3,766

3,466

175

4,919

390

3

592

-2,119

1,505

1,076

1,665

3,202

333

-1,027

-535

-1,456

-1,544

225

-28

96

633

-565

0

0

0

-

-

-

-

-

-

-

-

Accrued royalties

845

-3,372

-1,928

-1,954

-5,921

-3,708

-4,286

-3,661

1,030

-417

-653

3,145

1,192

6,269

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued compensation and related expenses

-

-

-

-

-

-

-

-

-

-

0

0

413

-

407

227

209

-160

286

152

47

575

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Current income taxes, net

11,770

-6,098

-1,132

-1,708

3,515

6,184

2,370

2,257

-3,718

-3,560

-1,123

-3,841

4,806

3,525

43

872

-1,631

-5,380

-2,116

-1,045

426

4,233

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Accrued government rebates

-522

-73

170

5,687

2,081

1,044

3,259

1,722

1,816

2,039

-696

-2,975

1,231

1,260

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Returned goods reserve

4,055

4,043

5,105

4,892

4,539

4,278

2,523

2,206

3,244

2,518

4,218

4,249

3,110

3,108

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued expenses, accrued compensation, and other

4

424

1,068

553

765

968

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued Medicaid rebates

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Accrued expenses and other

-

-

-

-

-

-

-

-

-

-

0

0

991

-

773

2,353

200

90

1,341

513

1,261

240

1,185

658

51

-67

0

0

0

-

-

-

-

-

-

-

-

Convertible note fair value adjustment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2,594

-23

0

0

0

Accounts payable and accrued liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-5,340

134

0

0

0

Net Cash and Cash Equivalents Provided by Operating Activities

33,050

45,631

68,060

54,586

58,435

67,074

55,647

64,412

55,820

39,419

35,696

19,696

23,032

27,472

0

0

0

-

-

-

-

22,033

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net Cash and Cash Equivalents Provided by Operating Activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-5,289

-2,862

-1,589

7,460

5

-10,437

-22,901

-45,085

-47,870

0

0

0

Acquisition of product rights, IPR&D, and other related assets

58,411

20,914

21,243

20,834

23,679

5,169

51,837

51,837

46,668

97,624

50,956

50,956

111,268

144,494

144,494

170,494

110,182

30,500

30,500

26,617

26,617

34,634

34,634

12,517

12,517

0

0

0

0

-

-

-

-

-

-

-

-

Acquisition of property and equipment, net

6,399

6,635

5,939

5,788

5,240

5,743

8,183

9,291

10,509

10,369

8,311

6,920

5,335

4,566

4,282

3,961

3,440

2,183

1,416

1,059

1,114

1,120

811

434

201

191

377

350

345

292

151

246

552

719

0

0

0

Net Cash and Cash Equivalents Used in Investing Activities

-64,810

-27,549

-26,582

-43,089

-45,386

-27,379

-77,087

-61,128

-57,177

-107,993

-59,267

-57,876

-116,603

-149,060

-148,776

-174,455

-113,622

-32,683

-31,916

-27,676

-27,731

-35,754

-33,185

-10,691

7,740

20,267

17,820

17,847

-337

-292

-151

-246

-560

-719

0

0

0

Purchase of investment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Cash Flows From Financing Activities
Borrowings under Revolver agreement

0

-

-

-

0

-

-

-

-

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net proceeds from equity offering

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

46,680

46,680

46,680

46,694

0

0

0

0

-

-

-

-

-

-

-

-

Payment of debt issuance costs

-

-

-

-

-

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payments on Term loan agreement

2,707

2,707

2,743

2,777

2,777

2,813

1,875

938

938

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Repayment of line of credit, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-4,065

0

0

0

-

-

-

-

-

-

-

-

Proceeds from stock option exercised

3,603

5,738

5,013

5,086

3,883

2,978

2,979

2,833

1,839

353

399

1,197

1,451

1,570

1,410

1,079

954

819

813

320

85

819

777

743

743

0

0

0

0

-

-

-

-

-

-

-

-

Proceeds from warrant exercise

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

750

989

989

989

809

0

0

0

-

-

-

-

-

-

-

-

Excess tax benefit from share-based compensation awards

-

-

-

-

-

-

-

-

-

-

-

-

-

617

433

332

352

360

586

823

686

784

432

8

107

0

0

0

0

-

-

-

-

-

-

-

-

Repurchase of common stock under the stock repurchase program

-

-

-

-

-

-

-

-

-

-

-

-

-

2,500

2,500

2,500

2,500

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Treasury stock purchases for restricted stock vests

1,211

1,031

1,031

1,031

717

659

659

659

509

259

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net Cash and Cash Equivalents (Used in)/Provided by Continuing Operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

740

-12,271

20,032

-1,875

19,069

0

0

0

Proceeds from issuance of common stock by registered direct offering

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

23,876

0

0

0

Net Cash and Cash Equivalents Provided by Financing Activities

13,935

1,250

-25,930

-25,891

-26,780

-27,816

47,555

43,346

42,502

72,357

25,450

31,536

31,651

-729

-1,073

-1,505

-1,307

1,066

124,476

124,220

123,947

171,653

48,878

48,420

43,663

-3,689

0

0

0

-

-

-

-

67,660

0

0

0

Change in Cash, Cash Equivalents, and Restricted Cash

-17,825

19,332

15,548

-14,394

-13,731

11,879

26,115

46,630

41,145

3,783

1,879

-6,644

-61,920

-122,317

-129,757

-146,716

-87,816

-14,353

115,863

113,770

114,190

157,932

24,120

40,366

51,332

11,094

0

0

0

-

-

-

-

-

-

-

-

Supplemental disclosure for cash flow information:
Cash paid for interest, net of amounts capitalized

7,491

6,092

6,149

6,043

6,281

6,285

5,325

4,841

4,212

3,759

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

250

0

0

0

-

-

-

-

-

-

-

-

Cash paid for income taxes

10,128

10,033

0

0

0

-

-

-

-

17,786

16,183

17,213

7,898

9,537

8,434

6,011

8,869

13,255

10,678

9,537

6,116

147

137

60

60

0

0

0

0

-

-

-

-

-

-

-

-

Supplemental non-cash investing and financing activities:
Acquisition of product rights, IPRED and other related assets included in accounts payable

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued royalties related to asset purchase

-

-

-

-

-

-

-

-

-

-

-

-

-

3,882

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Property and equipment purchased and included in accounts payable

691

723

890

421

655

521

241

609

443

485

499

311

240

247

432

434

419

439

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

21

0

0

0

Preferred stock dividends accrued

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,975

0

0

0

-

-

-

-

-

-

-

-

Property and equipment purchased on credit

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Shares issued for convertible senior notes and accrued interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-